Literature DB >> 2649160

Treatment of chronic schizophrenia with cyproheptadine.

H Silver1, M Blacker, M P Weller, B Lerer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2649160     DOI： 10.1016/0006-3223(89)90206-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  5 in total

Review 1.  5-HT2 antagonism and EPS benefits: is there a causal connection?

Authors:  S Kapur
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine.

Authors:  H Y Meltzer; M Maes; M A Lee
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.

Authors:  S Nyberg; L Farde; L Eriksson; C Halldin; B Eriksson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.

Authors:  Shahin Akhondzadeh; Hassan Mohajari; Mohammad Reza Mohammadi; Homayoun Amini
Journal:  BMC Psychiatry       Date:  2003-06-19       Impact factor: 3.630
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.